Toxicological Problems
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
WHO Drug Information Vol. 12, No. 3, 1998
WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic -
(12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn Et Al
US 2004O224012A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2004/0224012 A1 Suvanprakorn et al. (43) Pub. Date: Nov. 11, 2004 (54) TOPICAL APPLICATION AND METHODS Related U.S. Application Data FOR ADMINISTRATION OF ACTIVE AGENTS USING LIPOSOME MACRO-BEADS (63) Continuation-in-part of application No. 10/264,205, filed on Oct. 3, 2002. (76) Inventors: Pichit Suvanprakorn, Bangkok (TH); (60) Provisional application No. 60/327,643, filed on Oct. Tanusin Ploysangam, Bangkok (TH); 5, 2001. Lerson Tanasugarn, Bangkok (TH); Suwalee Chandrkrachang, Bangkok Publication Classification (TH); Nardo Zaias, Miami Beach, FL (US) (51) Int. CI.7. A61K 9/127; A61K 9/14 (52) U.S. Cl. ............................................ 424/450; 424/489 Correspondence Address: (57) ABSTRACT Eric G. Masamori 6520 Ridgewood Drive A topical application and methods for administration of Castro Valley, CA 94.552 (US) active agents encapsulated within non-permeable macro beads to enable a wider range of delivery vehicles, to provide longer product shelf-life, to allow multiple active (21) Appl. No.: 10/864,149 agents within the composition, to allow the controlled use of the active agents, to provide protected and designable release features and to provide visual inspection for damage (22) Filed: Jun. 9, 2004 and inconsistency. US 2004/0224012 A1 Nov. 11, 2004 TOPCAL APPLICATION AND METHODS FOR 0006 Various limitations on the shelf-life and use of ADMINISTRATION OF ACTIVE AGENTS USING liposome compounds exist due to the relatively fragile LPOSOME MACRO-BEADS nature of liposomes. Major problems encountered during liposome drug Storage in vesicular Suspension are the chemi CROSS REFERENCE TO OTHER cal alterations of the lipoSome compounds, Such as phos APPLICATIONS pholipids, cholesterols, ceramides, leading to potentially toxic degradation of the products, leakage of the drug from 0001) This application claims the benefit of U.S. -
GABA Receptors
D Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews • BIOTREND Reviews Review No.7 / 1-2011 GABA receptors Wolfgang Froestl , CNS & Chemistry Expert, AC Immune SA, PSE Building B - EPFL, CH-1015 Lausanne, Phone: +41 21 693 91 43, FAX: +41 21 693 91 20, E-mail: [email protected] GABA Activation of the GABA A receptor leads to an influx of chloride GABA ( -aminobutyric acid; Figure 1) is the most important and ions and to a hyperpolarization of the membrane. 16 subunits with γ most abundant inhibitory neurotransmitter in the mammalian molecular weights between 50 and 65 kD have been identified brain 1,2 , where it was first discovered in 1950 3-5 . It is a small achiral so far, 6 subunits, 3 subunits, 3 subunits, and the , , α β γ δ ε θ molecule with molecular weight of 103 g/mol and high water solu - and subunits 8,9 . π bility. At 25°C one gram of water can dissolve 1.3 grams of GABA. 2 Such a hydrophilic molecule (log P = -2.13, PSA = 63.3 Å ) cannot In the meantime all GABA A receptor binding sites have been eluci - cross the blood brain barrier. It is produced in the brain by decarb- dated in great detail. The GABA site is located at the interface oxylation of L-glutamic acid by the enzyme glutamic acid decarb- between and subunits. Benzodiazepines interact with subunit α β oxylase (GAD, EC 4.1.1.15). It is a neutral amino acid with pK = combinations ( ) ( ) , which is the most abundant combi - 1 α1 2 β2 2 γ2 4.23 and pK = 10.43. -
Analytical Methods for Determination of Benzodiazepines. a Short Review
Cent. Eur. J. Chem. • 12(10) • 2014 • 994-1007 DOI: 10.2478/s11532-014-0551-1 Central European Journal of Chemistry Analytical methods for determination of benzodiazepines. A short review Review Article Paulina Szatkowska1, Marcin Koba1*, Piotr Kośliński1, Jacek Wandas1, Tomasz Bączek2,3 1Department of Toxicology, Faculty of Pharmacy, Collegium Medicum of Nicolaus Copernicus University, 85-089 Bydgoszcz, Poland 2Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Gdańsk, 80-416 Gdańsk, Poland 3Institute of Health Sciences, Division of Human Anatomy and Physiology, Pomeranian University of Słupsk, 76-200 Słupsk, Poland Received 16 July 2013; Accepted 6 February 2014 Abstract: Benzodiazepines (BDZs) are generally commonly used as anxiolytic and/or hypnotic drugs as a ligand of the GABAA-benzodiazepine receptor. Moreover, some of benzodiazepines are widely used as an anti-depressive and sedative drugs, and also as anti-epileptic drugs and in some cases can be useful as an adjunct treatment in refractory epilepsies or anti-alcoholic therapy. High-performance liquid chromatography (HPLC) methods, thin-layer chromatography (TLC) methods, gas chromatography (GC) methods, capillary electrophoresis (CE) methods and some of spectrophotometric and spectrofluorometric methods were developed and have been extensively applied to the analysis of number of benzodiazepine derivative drugs (BDZs) providing reliable and accurate results. The available chemical methods for the determination of BDZs in biological materials and pharmaceutical formulations are reviewed in this work. Keywords: Analytical methods • Benzodiazepines • Drugs analysis • Pharmaceutical formulations © Versita Sp. z o.o. 1. Introduction and long). For this reason, an application of these drugs became broader allowing their utility to a larger extent, Benzodiazepines have been first introduced into medical and at the same time, problems related to drug abuse practice in the 60s of the last century. -
Antimicrobial Activity of Apitoxin, Melittin and Phospholipase A2 of Honey Bee (Apis Mellifera) Venom Against Oral Pathogens
Anais da Academia Brasileira de Ciências (2015) 87(1): 147-155 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201520130511 www.scielo.br/aabc Antimicrobial activity of apitoxin, melittin and phospholipase A2 of honey bee (Apis mellifera) venom against oral pathogens LUÍS F. LEANDRO, CARLOS A. MENDES, LUCIANA A. CASEMIRO, ADRIANA H.C. VINHOLIS, WILSON R. CUNHA, ROSANA DE ALMEIDA and CARLOS H.G. MARTINS Laboratório de Pesquisas em Microbiologia Aplicada (LaPeMA), Universidade de Franca, Av. Dr. Armando Salles Oliveira, 201, Bairro Parque Universitário, 14404-600 Franca, SP, Brasil Manuscript received on November 19, 2013; accepted for publication on June 30, 2014 ABSTRACT In this work, we used the Minimum Inhibitory Concentration (MIC) technique to evaluate the antibacterial potential of the apitoxin produced by Apis mellifera bees against the causative agents of tooth decay. Apitoxin was assayed in natura and in the commercially available form. The antibacterial actions of the main components of this apitoxin, phospholipase A2, and melittin were also assessed, alone and in combination. The following bacteria were tested: Streptococcus salivarius, S. sobrinus, S. mutans, S. mitis, S. sanguinis, Lactobacillus casei, and Enterococcus faecalis. The MIC results obtained for the commercially available apitoxin and for the apitoxin in natura were close and lay between 20 and 40µg / mL, which indicated good antibacterial activity. Melittin was the most active component in apitoxin; it displayed very promising MIC values, from 4 to 40µg / mL. Phospholipase A2 presented MIC values higher than 400µg / mL. Association of mellitin with phospholipase A2 yielded MIC values ranging between 6 and 80µg / mL. -
Statistical Analysis Plan Statistical Center for HIV/AIDS Research & SCHARP Prevention SD Standard Deviation SI International System of Units
67$7,67,&$/$1$/<6,63/$1 $:((.)/(;,%/('26(23(1/$%(/ 08/7,&(17(5(;7(16,21678'<72(9$/8$7(7+( /21*7(506$)(7<$1'())(&7,9(1(662) /85$6,'21(,13(',$75,&68%-(&76 /XUDVLGRQH60/DWXGD 6WXG\1R' 9HUVLRQ1XPEHU)LQDO 9HUVLRQ'DWH1RY $XWKRUL]DWLRQ6LJQDWXUH3DJH $:((.)/(;,%/('26(23(1/$%(/08/7,&(17(5(;7(16,21 678'<72(9$/8$7(7+(/21*7(506$)(7<$1'())(&7,9(1(662) /85$6,'21(,13(',$75,&68%-(&76 $XWKRU 1DPH 'DWH 3RVLWLRQ6HQLRU 'LUHFWRU%LRVWDWLVWLFV &RPSDQ\6XQRYLRQ3KDUPDFHXWLFDOV,QF $SSURYHGE\ 1DPH 'DWH 3RVLWLRQ 6HQLRU'LUHFWRU&OLQLFDO'HYHORSPHQW DQG0HGLFDO$IIDLUV&16 &RPSDQ\6XQRYLRQ3KDUPDFHXWLFDOV,QF 1DPH 'DWH 3RVLWLRQ([HFXWLYH'LUHFWRU%LRVWDWLVWLFV &RPSDQ\6XQRYLRQ3KDUPDFHXWLFDOV,QF Table of contents 1. INTRODUCTION ........................................................................................................9 1.1. Study Objectives ...........................................................................................................9 1.2. Study Design ...............................................................................................................10 1.2.1. Determination of Sample Size ....................................................................................11 1.2.2. Randomization and Blinding ......................................................................................11 2. ANALYSES PLANNED ............................................................................................12 2.1. General Analysis Definition .......................................................................................12 2.1.1. Logic -
Pharmaceuticals As Environmental Contaminants
PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational -
Edible Insects and Other Invertebrates in Australia: Future Prospects
Alan Louey Yen Edible insects and other invertebrates in Australia: future prospects Alan Louey Yen1 At the time of European settlement, the relative importance of insects in the diets of Australian Aborigines varied across the continent, reflecting both the availability of edible insects and of other plants and animals as food. The hunter-gatherer lifestyle adopted by the Australian Aborigines, as well as their understanding of the dangers of overexploitation, meant that entomophagy was a sustainable source of food. Over the last 200 years, entomophagy among Australian Aborigines has decreased because of the increasing adoption of European diets, changed social structures and changes in demography. Entomophagy has not been readily adopted by non-indigenous Australians, although there is an increased interest because of tourism and the development of a boutique cuisine based on indigenous foods (bush tucker). Tourism has adopted the hunter-gatherer model of exploitation in a manner that is probably unsustainable and may result in long-term environmental damage. The need for large numbers of edible insects (not only for the restaurant trade but also as fish bait) has prompted feasibility studies on the commercialization of edible Australian insects. Emphasis has been on the four major groups of edible insects: witjuti grubs (larvae of the moth family Cossidae), bardi grubs (beetle larvae), Bogong moths and honey ants. Many of the edible moth and beetle larvae grow slowly and their larval stages last for two or more years. Attempts at commercialization have been hampered by taxonomic uncertainty of some of the species and the lack of information on their biologies. -
Mental Disorders and Illicit Drug Use Expert Group
Global Burden of Disease Mental Disorders and Illicit Drug Use Expert Group Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Benzodiazepine-related mortality Illicit Drugs Discussion Paper No. 1 GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au BENZODIAZEPINE-RELATED MORTALITY Fiona Charlson, Louisa Degenhardt, Jennifer McLaren, Wayne Hall and Michael Lynskey Illicit Drugs Discussion Paper No. 1 Recommended citation: Charlson, F., Degenhardt, L., McLaren, J., Hall, W., & Lynskey, M. (2008). Benzodiazepine- related mortality. Global Burden of Disease Mental Disorders and Illicit Drug Use Expert group, Illicit drugs discussion paper No. 1. National Drug and Alcohol Research Centre, University of NSW: Sydney. ISBN: 978 0 7334 2688 9 ©NATIONAL DRUG AND ALCOHOL RESEARCH CENTRE, UNIVERSITY OF NEW SOUTH WALES, SYDNEY, 2008 This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, National Drug and Alcohol Research Centre, University of New South Wales, Sydney,NSW 2052, Australia. GBD2005 Mental Disorders and Illicit Drug Use Expert Group www.gbd.unsw.edu.au Table of contents Summary and recommendations .............................................................................................. 1 1. Introduction -
Muscle Relaxants for Pain Management in Rheumatoid Arthritis (Review)
Muscle relaxants for pain management in rheumatoid arthritis (Review) Richards BL, Whittle SL, Buchbinder R This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration and published in The Cochrane Library 2012, Issue 1 http://www.thecochranelibrary.com Muscle relaxants for pain management in rheumatoid arthritis (Review) Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . ..... 3 BACKGROUND .................................... 6 OBJECTIVES ..................................... 7 METHODS ...................................... 7 RESULTS....................................... 10 Figure1. ..................................... 11 Figure2. ..................................... 13 Figure3. ..................................... 15 Figure4. ..................................... 15 Figure5. ..................................... 16 Figure6. ..................................... 17 Figure7. ..................................... 17 Figure8. ..................................... 18 DISCUSSION ..................................... 20 AUTHORS’CONCLUSIONS . 21 ACKNOWLEDGEMENTS . 22 REFERENCES ..................................... 22 CHARACTERISTICSOFSTUDIES . 24 DATAANDANALYSES. 35 Analysis 1.1. Comparison 1 Muscle relaxant versus control, Outcome 1 Pain 24hrs. 37 Analysis 1.2. Comparison 1 Muscle relaxant -
Alphabetical Listing of ATC Drugs & Codes
Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04 -
The Effect of Bee Venom Peptides Melittin, Tertiapin, and Apamin On
H OH metabolites OH Article The Effect of Bee Venom Peptides Melittin, Tertiapin, and Apamin on the Human Erythrocytes Ghosts: A Preliminary Study 1, 2, 1 3 Agata Swiatły-Błaszkiewicz´ y, Lucyna Mrówczy ´nska y, Eliza Matuszewska , Jan Lubawy , Arkadiusz Urba ´nski 3 , Zenon J. Kokot 1, Grzegorz Rosi ´nski 3 and Jan Matysiak 1,* 1 Department of Inorganic and Analytical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland; [email protected] (A.S.-B.);´ [email protected] (E.M.); [email protected] (Z.J.K.) 2 Department of Cell Biology, Faculty of Biology, Adam Mickiewicz University in Poznan, 61-614 Poznan, Poland; [email protected] 3 Department of Animal Physiology and Development, Faculty of Biology, Adam Mickiewicz University in Poznan, 61-614 Poznan, Poland; [email protected] (J.L.); [email protected] (A.U.); [email protected] (G.R.) * Correspondence: [email protected] These two authors contributed equally to this work. y Received: 11 April 2020; Accepted: 11 May 2020; Published: 13 May 2020 Abstract: Red blood cells (RBCs) are the most abundant cells in the human blood that have been extensively studied under morphology, ultrastructure, biochemical and molecular functions. Therefore, RBCs are excellent cell models in the study of biologically active compounds like drugs and toxins on the structure and function of the cell membrane. The aim of the present study was to explore erythrocyte ghost’s proteome to identify changes occurring under the influence of three bee venom peptides-melittin, tertiapin, and apamin. We conducted preliminary experiments on the erythrocyte ghosts incubated with these peptides at their non-hemolytic concentrations.